Youssefyeh, R. D.; Campbell, H. F.; Klein, S.; Airey, J. E.; Darkes, P.; Powers, M.; Schnapper, M.; Neuenschwander, K.; Fitzpatrick, L. R. published the artcile< Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides>, Reference of 120570-05-0, the main research area is benzamide quinuclidinyl serotonin receptor antagonist; antiemetic quinuclidinyl benzamide.
Novel benzamides, e.g. I (X = H, Cl, Br, n = 1; X = Cl, n = 2), II (R = Me, Me2CHCH2, CH2:CHCHMe, MeCOCHMe), and S-III which are orally active, highly potent, specific antagonists of serotonin 5-HT3 receptors were prepared and the structure-activity relationships that led to these novel structures with improved potency in selectivity are described. (S)-III was identified and selected for further evaluation as a 5-HT3 receptor antagonist. Compared with 5-HT3 antagonists such as GR 38032F, BRL 43694, and metoclopramide, (S)-III was most active in (a) inhibiting binding to 5-HT3 receptor binding sites in rat entorhinal cortex with a Ki value of 0.19 nM and (b) blocking cisplatin-induced emesis in the ferret with an ED50 value determined to be 9 mg/kg, i.d.
Journal of Medicinal Chemistry published new progress about 5-HT antagonists. 120570-05-0 belongs to class quinuclidine, and the molecular formula is C7H14N2, Reference of 120570-05-0.
Referemce:
Quinuclidine – Wikipedia,
Quinuclidine | C7H13N | ChemSpider